Comprehensive Clinical Development
, formerly operating as Comprehensive NeuroScience, Inc., a clinical services company delivering high-quality clinical trials from Phase I-IV with three pharmacology units and five patient-focused Phase IIb-IV centers, has established its new brand identity, “Confidence in Comprehensive,” emphasizing the Company’s proficiency in conducting effective and efficient clinical trials.
Comprehensive
will unveil its new identity at the 2011 Drug Information Association (DIA) Annual Meeting , June 19-23, 2011, in Chicago, Illinois. Showcasing its total rebrand, Comprehensive will capitalize on its commitment to delivering efficient studies conducted with high quality and pristine data at booth #1539 during the annual meeting.
The new face of Comprehensive reflects the Company’s diverse therapeutic expertise and suite of clinical services. Articulating Comprehensive’s depth and breadth in therapeutic expertise with the rebrand, Comprehensive’s unwavering commitment to both its internal and external customers remains.
During the DIA Annual Meeting, Royce A. Morrison, M.D., M.S., Comprehensive Clinical Development’s chief medical officer, will present his findings on technology in early phase studies and strategies to optimize the methods utilized. His presentation, Track 4 (A), titled, “Nonclinical and Early Clinical Translational Development,” is scheduled for Wednesday, June 22, from 1:30 – 3:00 p.m.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.